The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

15 Apr 2020 07:00

RNS Number : 6520J
e-Therapeutics plc
15 April 2020
 

TR-1: Standard form for notification of major holdings

 

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

 

E-Therapeutics Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Robert Quested

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

14th April 2020

6. Date on which issuer notified (DD/MM/ YYYY):

14th April 2020

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments

(total of 8.B 1 + 8.B 2)

 

Total of both in % (8.A + 8.B)

 

Total number of voting rights of issuervii

 

Resulting situation on the date on which threshold was crossed or reached

 

4.6%

 

322,427,853

Position of previous notification (if applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00B2823H99

14,835,834

.0.00%

4.6%

0.00%

SUBTOTAL 8. A

14,835,834

4.6%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

 

Type of financial instrument

 

Expiration datex

 

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is exercised/converted.

 

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

 

Type of financial instrument

Expiration datex

Exercise/ Conversion Period xi

Physical or cash settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

X

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

 

Namexv

 

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

 

Total of both if it equals or is higher than the notifiable threshold

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

Place of completion

UK

Date of completion

14/04/20

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLEAELLFFKEEAA
Date   Source Headline
24th May 20116:30 pmRNSDirector/PDMR Shareholding
23rd May 20115:59 pmRNSDirector/PDMR Shareholding
15th Mar 20112:47 pmRNSDirector/PDMR Shareholding
15th Mar 201110:35 amRNSHolding(s) in Company
14th Mar 201112:00 pmRNSDirector/PDMR Shareholding
10th Mar 201111:07 amRNSRe-statement of Directors' Interests
10th Mar 201110:20 amRNSHolding(s) in Company
8th Mar 20116:11 pmRNSHolding(s) in Company
8th Mar 20116:01 pmRNSHolding(s) in Company
7th Mar 20118:22 amRNSCompletion of the Placings
4th Mar 20119:13 amRNSDirector/PDMR Shareholding
3rd Mar 20112:08 pmRNSResult of General Meeting
2nd Mar 20119:28 amRNSDirector/PDMR Shareholding
15th Feb 20117:30 amRNSIssue of Equity
3rd Feb 201112:09 pmRNSIssue of Equity
6th Dec 20107:00 amRNSDirectorate Change
29th Oct 20107:00 amRNSe-Therapeutics plc Interim Results
22nd Sep 20107:00 amRNSComprehensive Set of Patents Granted in US
8th Sep 201010:24 amRNSAGM Statement
30th Jul 20108:00 amRNSAnnual Financial Report
29th Jul 201010:23 amRNSAdditional Listing
2nd Jul 20108:00 amRNSDirectors' Interests
29th Jun 20107:00 amRNSFinal Results
25th May 20107:30 amRNSChange of Adviser
29th Apr 20109:02 amRNSIssue of Equity
29th Apr 20107:00 amRNSPre-close operational update and notice of Results
10th Mar 20104:01 pmRNSDirector's interest
2nd Mar 20109:30 amRNSDirector's shareholdings
15th Feb 20107:00 amRNSContract for iGCP trials with Infinitus
11th Nov 20095:46 pmRNSHolding(s) in Company
2nd Nov 200912:00 pmRNSPlacing
30th Oct 20097:00 amRNSInterim results
2nd Sep 200910:05 amRNSResult of AGM
11th Aug 20097:00 amRNSNotice of AGM
27th Jul 20097:42 amRNSPreliminary Results
14th Jul 20097:00 amRNSNotice of Results
25th Jun 20091:00 pmRNSChange of Adviser
17th Jun 20094:05 pmRNSDirector/PDMR Shareholding
9th Jun 200911:36 amRNSDirector Declaration
16th Mar 20094:34 pmRNSResult of General Meeting
11th Mar 20092:19 pmRNSDirector/PDMR Shareholding
25th Feb 20093:00 pmRNSNotice of General Meeting
25th Feb 20097:00 amRNSConditional Investment & Notice of General Meeting
24th Feb 20097:00 amRNSRevenue share agreement with Khandelwal
26th Jan 20097:00 amRNSStrategic Partnership
14th Jan 20097:00 amRNSPositive Phase IIa results for antidepressant
12th Jan 20091:23 pmRNSUS patent granted
12th Nov 20085:04 pmRNSShare Option Award
11th Nov 20083:02 pmRNSGrant of patents
31st Oct 20087:00 amRNSDirector's Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.